Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 8/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 6/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263578 | 0.90 | MAPT (0.46) | MAPTLMNAPTPN1TP53THRB | |
| SCHEMBL260793 | 0.87 | MAPT (0.47) | MAPTLMNAPTPN1TP53THRB | |
| SCHEMBL260977 | 0.86 | MAPT (0.44) | MAPTLMNATP53THRB | |
| SCHEMBL260420 | 0.84 | PTPN1 (0.39) | MAPTLMNAPTPN1TP53THRB | |
| SCHEMBL261446 | 0.84 | MAPT (0.46) | MAPTLMNATP53THRB | |
| SCHEMBL259721 | 0.82 | MAPT (0.53) | MAPTLMNATP53 | |
| SCHEMBL260581 | 0.82 | RAB9A (0.53) | MAPTLMNATP53THRB | |
| SCHEMBL260156 | 0.82 | MAPT (0.39) | MAPTLMNAPTPN1TP53THRB | |
| SCHEMBL260042 | 0.82 | TP53 (0.49) | MAPTLMNATP53THRB | |
| SCHEMBL3971233 | 0.81 | TP53 (0.38) | MAPTLMNAPTPN1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | claimed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-09-25 | — | — | US | disclosed |
| US-7332513-B2 | Thiazole-based nitric oxide donors having acyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-02-19 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | MAPT 4020/4885LMNA 4210/4885PTPN1 643/4885 |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | MAPT 3098/4885LMNA 4357/4885PTPN1 826/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | MAPT 4152/4885LMNA 4412/4885PTPN1 878/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | MAPT 4020/4885LMNA 4210/4885PTPN1 643/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | MAPT 3663/4885LMNA 4082/4885PTPN1 1058/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | MAPT 4219/4885LMNA 3973/4885PTPN1 2328/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | MAPT 4115/4885LMNA 3851/4885PTPN1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.